Printer Friendly

Genentech antibody patent issues - licensed to MedImmune.

Genentech, Inc. (S. San Francisco, CA; 650-225-1000) has been granted a patent relating to certain methods and compositions used to produce antibodies by recombinant DNA technology. This patent had been filed by Genentech with a priority date of 1983. Today, a number of biotechnology companies, including MedImmune, Inc. (Gaithersburg, MD; 301-527-4321), utilize methods of recombinant DNA technology in the production of their antibody-based products. In anticipation of any potential impact the issuance of this patent could have, four years ago, MedImmune obtained a license to Genentech's antibody production patent for MedImmune's antibody-based product Synagis (palivizumab).

MedImmune is in the process of evaluating whether any valid claim of Genentech's patent, as recently issued, covers production of Synagis. If so, MedImmune would pay royalties to Genentech on United States net sales of Synagis commencing December 18, 2001. MedImmune anticipates that incremental Synagis royalties to Genentech, if any, would not change its prior financial guidance issued on December 3, 2001. MedImmune is also evaluating whether any of its other antibody-based product candidates, if and when approved for marketing by the United States Food and Drug Administration, could require a license under the Genentech patent . There can be no assurance that if such a license were required and available, it would be available on terms acceptable to MedImmune.

Synagis (palivizumab) is marketed for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in pediatric patients at high risk of RSV disease, which is prominent in the Northern Hemisphere from October through May.

MedImmune is a biotechnology company focused on developing and marketing products that address medical needs in areas such as infectious disease, immune regulation and cancer. MedImmune has manufacturing facilities in Frederick, Maryland and Nijmegen, the Netherlands.
COPYRIGHT 2001 Biotech Patent News
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Comment:Genentech antibody patent issues - licensed to MedImmune.
Publication:BIOTECH Patent News
Article Type:Brief Article
Geographic Code:1USA
Date:Dec 1, 2001
Words:288
Previous Article:Affymetrix and Incyte settle all patent litigation.
Next Article:ID Biomedical begins trivalent nasal flu vaccine study.
Topics:


Related Articles
Protein Design grants license to Celltech under patent.
Celltech and Genentech settle Boss/Cabilly antibody patent interference.
Tanox enters licensing agreement for Its cancer gene.
Abgenix and Genentech extend antibody technology licensing agreement.
Survey shows Supreme Court ruling may hinder licensing.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters